ProCE Banner Activity

Getting Out of the Gray Zone: Earlier Treatment for HBV Infection

Clinical Thought

Evidence shows that patients with HBV infection who do not meet current treatment criteria may still benefit from treatment. Read expert perspectives on current HBV treatment guideline recommendations and their limitations, as well as primary considerations for more expansive HBV treatment.

Released: April 04, 2024

Expiration: April 03, 2025

Share

Faculty

Tatyana Kushner

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

Hepatitis B Foundation

ProCE Banner

Disclosure

Primary Author

Tatyana Kushner, MD, MSCE

Associate Professor
Division of Gastroenterology/ Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York

Tatyana Kushner, MD, MSCE: consultant/advisor/speaker: AbbVie, Eiger, Gilead, GlaxoSmithKline; researcher: Gilead.